Plasma Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) as a Possible Biomarker for Severe COVID-19

URN to cite this document:: urn:nbn:de:bvb:355-epub-544558
DOI to cite this document:: 10.5283/epub.54455

Mester, Patricia ; Amend, Pablo ; Schmid, Stephan

; Müller, Martina ; Buechler, Christa

; Pavel, Vlad

License: Creative Commons Attribution 4.0
PDF - Published Version
(1MB)

Date of publication of this fulltext: 24 Jul 2023 15:43

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces low density lipoprotein (LDL) uptake, leading to increased plasma levels of LDL. In addition, PCSK9 has been implicated in inflammation independently of the effects on cholesterol metabolism. The current analysis showed that our 156 patients with systemic inflammatory response syndrome (SIRS) or sepsis had higher plasma PCSK9 levels in ...